IL257748A - תחליפי פירזולו[4,3–b] פירידינים כתרופות - Google Patents
תחליפי פירזולו[4,3–b] פירידינים כתרופותInfo
- Publication number
- IL257748A IL257748A IL257748A IL25774818A IL257748A IL 257748 A IL257748 A IL 257748A IL 257748 A IL257748 A IL 257748A IL 25774818 A IL25774818 A IL 25774818A IL 257748 A IL257748 A IL 257748A
- Authority
- IL
- Israel
- Prior art keywords
- group
- compound
- use according
- atom
- optionally substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 229910020008 S(O) Inorganic materials 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- DBTDEFJAFBUGPP-UHFFFAOYSA-N Methanethial Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 claims 1
- 101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000019256 formaldehyde Nutrition 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1150651A FR2970967B1 (fr) | 2011-01-27 | 2011-01-27 | Derives de type azaindazole ou diazaindazole comme medicament |
PCT/EP2012/051283 WO2012101239A1 (en) | 2011-01-27 | 2012-01-27 | Derivatives of azaindazole or diazaindazole type as medicament |
Publications (2)
Publication Number | Publication Date |
---|---|
IL257748A true IL257748A (he) | 2018-04-30 |
IL257748B IL257748B (he) | 2020-06-30 |
Family
ID=44318089
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL227496A IL227496B (he) | 2011-01-27 | 2013-07-16 | פיראזולו[4,3–b]פירידינים מותמרים כתרופות |
IL257748A IL257748B (he) | 2011-01-27 | 2018-02-26 | נגזרות של פירזול [ 4,3 –b] פירידין, פירזולו [ 4, 3 –b] פירידין ופירזולו [ 4,3 –b] פיריזין לשימוש בטיפול בסרטן, מחלות דלקתיות ומחלות נוירודגנרטיביות, |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL227496A IL227496B (he) | 2011-01-27 | 2013-07-16 | פיראזולו[4,3–b]פירידינים מותמרים כתרופות |
Country Status (31)
Country | Link |
---|---|
US (2) | US20130172360A1 (he) |
EP (1) | EP2668184B1 (he) |
JP (1) | JP5931926B2 (he) |
KR (2) | KR101923751B1 (he) |
CN (1) | CN103339129B (he) |
AR (1) | AR084935A1 (he) |
AU (1) | AU2012210467B2 (he) |
BR (1) | BR112013018852B1 (he) |
CA (1) | CA2823824C (he) |
CY (1) | CY1120088T1 (he) |
DK (1) | DK2668184T3 (he) |
ES (1) | ES2661695T3 (he) |
FR (1) | FR2970967B1 (he) |
HK (1) | HK1186737A1 (he) |
HR (1) | HRP20180524T1 (he) |
HU (1) | HUE037153T2 (he) |
IL (2) | IL227496B (he) |
LT (1) | LT2668184T (he) |
MA (1) | MA34903B1 (he) |
MX (1) | MX356411B (he) |
MY (1) | MY180666A (he) |
PL (1) | PL2668184T3 (he) |
PT (1) | PT2668184T (he) |
RS (1) | RS57101B1 (he) |
RU (1) | RU2600976C2 (he) |
SI (1) | SI2668184T1 (he) |
TN (1) | TN2013000293A1 (he) |
TR (1) | TR201802944T4 (he) |
TW (1) | TWI546303B (he) |
UA (1) | UA109698C2 (he) |
WO (1) | WO2012101239A1 (he) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
US9458147B2 (en) | 2012-02-22 | 2016-10-04 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as TNAP inhibitors |
KR102406771B1 (ko) | 2012-06-13 | 2022-06-13 | 인사이트 홀딩스 코포레이션 | Fgfr 억제제로서 치환된 트리사이클릭 화합물 |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP3318564B1 (en) | 2013-04-19 | 2021-07-28 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10336707B2 (en) | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
US10211205B2 (en) * | 2016-04-27 | 2019-02-19 | International Business Machines Corporation | Field effect transistor structure for reducing contact resistance |
CN108570052A (zh) * | 2017-03-13 | 2018-09-25 | 中国科学院上海药物研究所 | 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
DK3788047T3 (da) | 2018-05-04 | 2024-09-16 | Incyte Corp | Faste former af en FGFR-inhibitor og fremgangsmåder til fremstilling deraf |
MA52493A (fr) | 2018-05-04 | 2021-03-10 | Incyte Corp | Sels d'un inhibiteur de fgfr |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN115916771A (zh) * | 2020-04-02 | 2023-04-04 | 浙江华海药业股份有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
MX2023005913A (es) * | 2020-11-20 | 2023-05-24 | 2692372 Ontario Inc | Derivados de bencenosulfonamida y usos de los mismos. |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID24653A (id) * | 1997-03-19 | 2000-07-27 | Basf Ag | Zat-zat terapi |
EP1215208B1 (en) | 1997-10-27 | 2006-07-12 | Agouron Pharmaceuticals, Inc. | 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases |
CA2411961C (en) | 2000-06-22 | 2007-02-06 | Pfizer Inc. | Novel process for the preparation of pyrazolopyrimidinones |
WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
JP2009506006A (ja) * | 2005-08-25 | 2009-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | p38MAPキナーゼ阻害剤およびその使用方法 |
WO2008010964A1 (en) | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
AU2007336335B8 (en) | 2006-12-20 | 2014-07-24 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
HUE030929T2 (en) | 2007-07-20 | 2017-06-28 | Nerviano Medical Sciences Srl | Substituted imidazole derivatives having kinase activity |
US8354399B2 (en) | 2008-12-18 | 2013-01-15 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
-
2011
- 2011-01-27 FR FR1150651A patent/FR2970967B1/fr active Active
-
2012
- 2012-01-20 TW TW101102531A patent/TWI546303B/zh active
- 2012-01-27 HU HUE12701884A patent/HUE037153T2/hu unknown
- 2012-01-27 MA MA36177A patent/MA34903B1/fr unknown
- 2012-01-27 CA CA2823824A patent/CA2823824C/en active Active
- 2012-01-27 WO PCT/EP2012/051283 patent/WO2012101239A1/en active Application Filing
- 2012-01-27 EP EP12701884.4A patent/EP2668184B1/en active Active
- 2012-01-27 TR TR2018/02944T patent/TR201802944T4/tr unknown
- 2012-01-27 PT PT127018844T patent/PT2668184T/pt unknown
- 2012-01-27 SI SI201231273T patent/SI2668184T1/en unknown
- 2012-01-27 CN CN201280006671.8A patent/CN103339129B/zh active Active
- 2012-01-27 DK DK12701884.4T patent/DK2668184T3/en active
- 2012-01-27 BR BR112013018852-9A patent/BR112013018852B1/pt active IP Right Grant
- 2012-01-27 PL PL12701884T patent/PL2668184T3/pl unknown
- 2012-01-27 RS RS20180418A patent/RS57101B1/sr unknown
- 2012-01-27 AR ARP120100272A patent/AR084935A1/es active IP Right Grant
- 2012-01-27 RU RU2013138624/04A patent/RU2600976C2/ru active
- 2012-01-27 KR KR1020137022330A patent/KR101923751B1/ko active IP Right Grant
- 2012-01-27 US US13/823,658 patent/US20130172360A1/en not_active Abandoned
- 2012-01-27 ES ES12701884.4T patent/ES2661695T3/es active Active
- 2012-01-27 MX MX2013008673A patent/MX356411B/es active IP Right Grant
- 2012-01-27 JP JP2013550886A patent/JP5931926B2/ja active Active
- 2012-01-27 MY MYPI2013002799A patent/MY180666A/en unknown
- 2012-01-27 LT LTEP12701884.4T patent/LT2668184T/lt unknown
- 2012-01-27 UA UAA201310425A patent/UA109698C2/ru unknown
- 2012-01-27 AU AU2012210467A patent/AU2012210467B2/en active Active
- 2012-01-27 KR KR1020187031264A patent/KR20180122028A/ko not_active Application Discontinuation
- 2012-11-27 US US13/686,334 patent/US8883821B2/en active Active
-
2013
- 2013-07-11 TN TNP2013000293A patent/TN2013000293A1/fr unknown
- 2013-07-16 IL IL227496A patent/IL227496B/he active IP Right Grant
- 2013-12-24 HK HK13114261.8A patent/HK1186737A1/xx unknown
-
2018
- 2018-02-26 IL IL257748A patent/IL257748B/he active IP Right Grant
- 2018-03-26 CY CY20181100338T patent/CY1120088T1/el unknown
- 2018-03-29 HR HRP20180524TT patent/HRP20180524T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257748A (he) | תחליפי פירזולו[4,3–b] פירידינים כתרופות | |
JP2018522027A5 (he) | ||
US9073927B2 (en) | Inhibitors of PI3 kinase | |
CA2394525A1 (en) | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | |
CA3018821C (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
RU2008117083A (ru) | Бициклические ароматические соединения, применяемые в качестве ингибиторов протеинкиназы-2, активируемой митогенактивируемой протеинкиназой | |
RU2011151835A (ru) | Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ | |
RU2012155606A (ru) | Гидроксилированные и метоксилированные циклопента[d]пиримидины в качестве ингибиторов акт протеинкиназ | |
CA2510534A1 (en) | Compositions useful as inhibitors of protein kinases | |
JPWO2020061101A5 (he) | ||
JP2012507567A5 (he) | ||
RU2005123802A (ru) | Производные адамантана, способы их получения и содержащие их фармацевтические композиции | |
US20190133985A1 (en) | Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas | |
JP2019069969A (ja) | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤 | |
US20220324820A1 (en) | Methods and compositions for gamma-glutamyl cycle modulation | |
EP1379508B1 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
HUP0102388A2 (hu) | Diazepino-indol-származékok alkalmazása krónikus obstruktív tüdőbetegség kezelésére szolgáló gyógyszerkészítmény előállítására | |
CN112703001A (zh) | 使用喹啉羧酰胺衍生物的癌症联用疗法 | |
EP3964217A4 (en) | USE OF A COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT, DIMERE OR TRIMERE THEREOF IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF CANCER | |
DE602004023394D1 (de) | Verfahren zur herstellung von acylsulfamoylbenzamiden | |
CA3079781A1 (en) | Il-8 inhibitors for use in the treatment of some sarcomas | |
Gladney et al. | Multiple myeloma presenting with advanced renal failure: a case report and new treatment options | |
Kempf et al. | Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease | |
Farlow et al. | ASO Author Reflections: Treatment of the Paratracheal Nodes in the Clinically Negative Neck in Salvage Laryngectomy | |
US20230190932A1 (en) | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |